Skip to main content

Security report for desitinpharma.com

Desitin Arzneimittel GmbH · Healthcare · Germany

Medium risk. 3 critical or high findings in GDPR outside view, SSL/TLS and 1 other check.

Security score

60/100

Risk levelMedium

0–100, higher is better. How it is calculated

Desitin Arzneimittel GmbH is a well-established European pharmaceutical company specializing in neurological and psychiatric therapies. The company operates with affiliates across multiple European countries, indicating a broad regional presence. Their website reflects a professional business model focused on pharmaceutical manufacturing, clinical development, regulatory expertise, and business development partnerships. The digital infrastructure is based on WordPress with modern technologies such as Bootstrap and Google Analytics, providing a good user experience and SEO optimization. Security posture is strong with HTTPS and cookie consent mechanisms, though some improvements like DNSSEC and security headers could enhance protection. Overall, the website is trustworthy, compliant with GDPR, and presents clear contact channels, though explicit security policies and incident response contacts are absent.

Scanned

NIS2 and GDPR posture

GDPR outside view
68/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

3 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1
  3. Network security

    Services reachable from the internet are the first thing attackers probe. Anything open that does not need to be should be closed.

    • High

      High-Risk Service Exposed: FTP

      Port 21 (FTP) is publicly accessible - FTP - Often unencrypted file transfer

      What to do: Consider restricting access to FTP or implementing strong authentication

      • NIS2 21(2)(e)
      • IR 2024/2690 6.7.2(f): Implementing Regulation (EU) 2024/2690, Annex point 6.7.2(f): Network security
      • NIST CM-7: NIST SP 800-53 Rev. 5 CM-7: Least Functionality
      • NIST SC-7: NIST SP 800-53 Rev. 5 SC-7: Boundary Protection

Need hands-on remediation? Email guard@offseq.com

Keep watching desitinpharma.com

This scan found 23 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
62
Security headers
80
Email security
70
DNS health
60
Network security
20
GDPR outside view
68
Average
60

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Breach exposure

Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.

Dark web exposure

Add-on

Leaked records that mention desitinpharma.com, from OffSeq Breach.

Total records
4
Employees
0
Customers
4
Third parties
0
Weak passwords
0%

2 subdomains affected

See the 10 newest leaked credentials

A one-off add-on to this report that lists the most recent identifier and password pairs OffSeq Breach holds for desitinpharma.com.

Select it in the checkout above.

Breach keeps ingesting new leaks, so these numbers can grow between scans.

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

The company holds a solid market position in the healthcare sector, targeting healthcare professionals and partners in Europe. Their business model includes licensing and manufacturing sophisticated pharmaceutical products. The presence of multiple country-specific affiliate domains suggests a decentralized but coordinated market approach. The website content and structure support business credibility and trust, with comprehensive legal and privacy documentation. The use of advanced marketing and analytics tools indicates a mature digital marketing strategy. No suspicious or fraudulent indicators were found, supporting a high legitimacy score.

Security posture

Security maturity is moderate to high, with HTTPS enforced and cookie consent implemented via Borlabs Cookie. However, the absence of DNSSEC and HTTP security headers represents areas for improvement. No vulnerabilities or exposed sensitive data were detected in the HTML content. The lack of a published security policy or incident response contact limits transparency in security governance. The website uses reputable third-party services like Google Analytics and Tag Manager, which are managed with user consent. Overall, the security posture is adequate for the business type but could benefit from formalized policies and enhanced DNS security.

Recommendations

  1. Enable DNSSEC on the domain to improve DNS integrity and security.
  2. Implement HTTP security headers such as Content-Security-Policy, Strict-Transport-Security, X-Frame-Options, and X-Content-Type-Options.
  3. Publish a dedicated security policy page and provide incident response contact information to improve transparency and trust.
  4. Regularly audit and update third-party scripts and plugins to mitigate potential vulnerabilities.
  5. Consider adding a vulnerability disclosure or security.txt file to facilitate responsible reporting.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Desitin Arzneimittel GmbH
Description
Desitin Arzneimittel GmbH is a European pharmaceutical company specialized in sophisticated products for the therapy of neurological and psychiatric diseases with affiliates in 9 European countries.
Key services
Pharmaceutical manufacturing, Clinical development, Regulatory expertise, Market access & healthcare, Business development and licensing
Content quality
good
Branding
consistent

Technology

Stack
WordPress, Yoast SEO plugin, jQuery, Bootstrap, Google Analytics 4, Google Tag Manager, Borlabs Cookie plugin
Frameworks
Bootstrap
Platforms
WordPress
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent banner with granular controls
  • No exposed sensitive data in HTML
  • Use of security plugins (Borlabs Cookie)

Analytics and tracking

Services
Google Analytics 4
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Google Analytics 4
Marketing tools
Borlabs Cookie
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is a professional pharmaceutical company site with clear business focus.
  2. Content is well structured with multiple language options and country-specific domains.
  3. Cookie consent and privacy policies are implemented with granular user controls.
  4. No signs of malicious or suspicious content.
  5. Use of modern web technologies and SEO best practices.
  6. No explicit security policy or incident response contact found.
  7. No security.txt or vulnerability disclosure page detected.
Technical notes

Notes

The website is built on WordPress CMS with a modern tech stack including Bootstrap for responsive design and jQuery for scripting. SEO is enhanced using Yoast SEO plugin, and analytics are handled via Google Analytics 4 and Google Tag Manager. The site loads with moderate performance and good mobile optimization. Fonts and assets are preloaded for performance. The hosting provider is not explicitly identified but DNS servers indicate COREhub, S.R.L. The site uses Borlabs Cookie for GDPR-compliant cookie management. There is no evidence of technical debt or deprecated technologies, but security headers are missing which is a technical risk. Overall, the technical implementation supports a professional and functional website.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with desitinpharma.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review desitinpharma.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.